Hematologic Malignancies Market Is Projected To Grow Rapidly Due To Growing Incidence Of Blood Cancer Till 2025: Grand View Research, Inc.
The
global hematologic malignancies market is estimated to
reach USD 85.8 billion by 2025, according to a new report by Grand View
Research, Inc. Increasing incidence of hematologic malignancies and presence of
a strong product pipeline are estimated to boost the market. Moreover,
increasing number of mergers and acquisitions are also expected to accelerate
growth.
Furthermore,
governments of developing countries are spending more on healthcare and on
improving healthcare infrastructure. This is likely to reduce out-of-pocket
expenditure for patients. which is considered as one of the major factors
driving the hematologic malignancies market.
Recently
it has been seen that the government sources are taking an initiative in
funding the institutes for breakthrough oncology research. This is a major growth
driver for the market as it will support the institutes to conduct their
research on a larger-scale without any financial constraints. Federal
government funding for research in oncology has led to a substantial
development in cancer detection, prevention, diagnosis, treatment and quality
of life for patients. Due to the advancement in cancer research, more patients
with cancer are being successfully treated. The increasing investment in cancer
research is expected to boost the growth of market during forecast period
Browse full research report on Hematologic
Malignancies Market: http://www.grandviewresearch.com/industry-analysis/hematologic-malignancies-market
Further
Key Findings From the Study Suggest:
- Multiple myeloma is expected to be one of the
fastest growing segments over the forecast period owing to strong pipeline
of blockbuster products
- Chronic myeloid leukemia was identified as the
largest leukemia subtype in 2016 due to availability of large number of
products and high number of target population
- Chemotherapy held the largest share in 2016 on
the basis of therapy due to its preference as first line of therapy and
wide product range
- Immunotherapy is anticipated to be the fastest
growing segment and this can be attributed to lower adverse effects and
higher efficiency
- North America dominated the market in 2016
owing to local presence of key players and increasing number of mergers
and acquisitions
- Asia Pacific is expected to be the fastest
growing region over the next decade with lucrative CAGR from 2017 to 2025
due to improving economic conditions and rising healthcare expenditure
- Some of the key players are Pfizer, Inc.; F.
Hoffmann-LA Roche Ltd; Sanofi; Bristol-Myers Squibb Company; AbbVie, Inc.;
Novartis AG; GlaxoSmithKline PLC; Celgene Corporation; Johnson &
Johnson Services, Inc.; and Takeda Pharmaceutical Company Limited
- Most of the key players are focusing on
expanding their product portfolios, development of new treatment, and
acquisitions.
Access
Press Release By Grand View Research: http://www.grandviewresearch.com/press-release/global-hematologic-malignancies-market
About
Grand View Research, Inc:
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, the company offers market intelligence
studies ensuring relevant and fact-based research across a range of industries
including technology, chemicals, materials, healthcare and energy.
Comments
Post a Comment